Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | OXTR | P30559 | 8/20 | 0.38 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856982 | 0.85 | TDO2 (0.46) | TDO2OXTRMLNRHRH3AVPR1A | |
| SCHEMBL16382664 | 0.83 | TDO2 (0.45) | SLC6A4TDO2OXTRAVPR1AAVPR2 | |
| SCHEMBL20147459 | 0.80 | SLC6A4 (0.45) | SLC6A4TDO2OXTRHRH3AVPR1A | |
| SCHEMBL25933724 | 0.77 | MAPT (0.56) | HRH3OPRK1 | |
| SCHEMBL31277351 | 0.77 | TDO2 (0.47) | TDO2OXTRMLNRHRH3AVPR1A | |
| SCHEMBL19865665 | 0.76 | TDO2 (0.54) | TDO2OXTRHRH3AVPR1A | |
| SCHEMBL19865633 | 0.76 | TDO2 (0.54) | TDO2OXTRHRH3AVPR1A | |
| SCHEMBL28613739 | 0.76 | HCRTR1 (0.38) | TDO2OXTRAVPR1AAVPR2 | |
| SCHEMBL25502963 | 0.76 | TDO2 (0.36) | TDO2OXTRMLNRAVPR1AAVPR2 | |
| SCHEMBL20069366 | 0.76 | TDO2 (0.54) | TDO2OXTRHRH3AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SLC6A4 3586/4885TDO2 4376/4885OXTR 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.